S&P 500 Industrials Sector SEC Filings — March 20, 2026

20-03-2026

Urban One, Inc. (UONEK) reported FY 2025 net revenue of $374.4M, down 16.7% YoY from $449.7M, with declines across all major segments including radio advertising (-14.6%), political advertising (-93.0%), digital advertising (-19.0%), cable TV advertising (-9.3%), and affiliate fees (-10.0%). Net loss attributable to common stockholders widened to $146.9M from $105.4M, driven by higher impairment charges of $191.8M (up 26.4%) and increased depreciation, despite lower operating expenses in programming (-7.3%) and SG&A (-7.8%), and a larger gain on debt retirement ($44.0M, +89.1%). Adjusted EBITDA fell sharply to $56.7M from $103.5M, while core radio local advertising mix rose to 63.4% from 59.8%, but national advertising share declined to 30.7% from 35.2%.

• ·Programming and technical expenses declined 7.3% to $125.4M.
• ·Corporate SG&A expenses stable at ~$50.8M.
• ·Depreciation and amortization rose to $18.1M from $7.7M.
• ·Interest expense decreased 20.1% to $38.8M.
• ·Net cash used in investing activities $10.3M; financing $105.1M.
• ·Goodwill impairment testing (as of May 31, 2025): discount rate 9.5%, projected revenue growth (34.5)% to 53.1%.

20-03-2026

Cogent Communications Holdings, Inc.'s DEF 14A proxy statement details corporate governance practices, including full attendance by directors at the 2025 annual meeting and independence of all directors except CEO Dave Schaeffer. For 2025 executive compensation, base salaries for non-CEO Named Executive Officers increased 2.5%, CEO incentives achieved 152% of AWR CAGR target ($333,500 earned) but only 79% of GP CAGR target ($196,743), and sales commissions reached 92% for Mark Harris ($141,900) while at 77% for former CRO James Bubeck ($80,813). Significant long-term incentive grants were awarded, including up to 551,177 RSU shares for the CEO for 2026 service based on $12M notional value.

• ·All directors except CEO determined independent per Nasdaq rules.
• ·CEO 2025 LTIPs: 84,000 time-based RSUs and 96,000 performance-based RSUs (half EBITDA CAGR, half Free Cash Flow CAGR through 2027).
• ·CEO 2026 LTIPs: 229,657 time-based RSUs vesting 2029 and 321,520 performance-based RSUs based on EBITDA CAGR through 2028.
• ·Supplemental 100,000 time-based RSUs each to Chang, Harris, Weed vesting 2029 for Sprint acquisition retention.
• ·Performance-based RSUs for Weed, Chang, Kilmer based on customer satisfaction or performance through 2028.

20-03-2026

InMed Pharmaceuticals Inc. filed an S-3 shelf registration statement on March 20, 2026 (SEC file number 333-294503), enabling potential future offerings of common shares, preferred shares, warrants, subscription rights, and units with no specified amount, for general corporate purposes including working capital and possible acquisitions. As of the prospectus date, the company has 2,919,186 common shares issued and outstanding held by 6,388 record holders, with no preferred shares outstanding. The filing incorporates risks from the FY ended June 30, 2025 10-K (filed September 23, 2025, amended October 24, 2025) and notes no anticipated cash dividends.

• ·Principal executive offices: Suite 1445, 885 West Georgia Street, Vancouver, BC, V6C 3E8; phone: +1-604-669-7207.
• ·Common shares traded as 'INM' on Nasdaq Capital Market.
• ·Originally incorporated May 19, 1981 in British Columbia; name changed to InMed Pharmaceuticals Inc. on October 6, 2014.
• ·Fiscal year end: June 30.
• ·Transfer agent: Odyssey Trust Company, Suite 702, 67 Yonge Street, Toronto, Ontario, M5E 1J8.

20-03-2026

Prestige Consumer Healthcare Inc. announced an agreement to acquire the Breathe Right portfolio, including the #1 nasal strip brand, from Foundation Consumer Healthcare for $1.045B in cash (~$900M net of anticipated tax benefits), adding ~$200M LTM revenue (ended Dec 31, 2025) and ~$95M EBITDA at 11.0x multiple (9.5x net). The deal is immediately accretive to revenue, margins, EPS, and FCF, boosting pro-forma revenue to ~$1.3B from standalone ~$1.1B, financed by cash and new term loan with pro-forma net leverage ~4.0x at close (expected H1 FY27) and path to <3.0x by FY28. Historically, FY20-FY25 CAGRs show revenue +3.4%, organic revenue +2.4%, and adjusted EPS +8.8%, reflecting steady but modest organic growth.

• ·Target portfolio: 71% US & Canada revenue, 29% international (mostly Europe).
• ·Breathe Right provides ~30% immediate nasal airflow increase; loyal users average 150+ strips/year.
• ·Acquisition expected to close H1 FY27 (by Sep 30, 2026), subject to regulatory approvals.
• ·Historical net leverage: 4.1x Q2 FY22, down to 2.4x FY25 and FY26E.
• ·Prestige FY25 adjusted net income $226.3M (GAAP $214.6M); FY20 adjusted $151.3M (GAAP $142.3M).

20-03-2026

This employee FAQ details the treatment of equity awards, FY 2026 bonuses, and severance under the National Storage Affiliates Trust Severance Plan amid Public Storage’s proposed acquisition of NSA. Unvested restricted shares and most Partnership LTIP Units vest fully prior to closing without requiring continued employment, while performance-based LTIP Units granted in 2026 are cancelled without payment. Eligible employees may receive prorated FY 2026 target bonuses and severance ranging from 4-52 weeks of pay based on tier and service, plus housing payments up to $3,000, but severance is not automatic and requires qualifying termination.

• ·Severance multiples for corporate employees: Tier 1 (SVPs) 20-52 weeks; Tier 2 (VPs) 16-36 weeks; Tier 3 (Directors) 12-24 weeks; Tier 4 (Managers) 8-16 weeks; Tier 5 (others) 4-12 weeks of weekly base pay plus bonus.
• ·Field employee severance: 4-12 weeks of base pay based on years of service tiers.
• ·FY 2026 bonus proration: days from January 1, 2026 to merger date divided by 365, paid after 90 days post-closing employment or upon qualifying termination with release.
• ·Housing eligibility: loss of NSA-provided housing within one year after March 16, 2026, while remaining employed.
• ·Reference to NSA OP Unitholder FAQ filed March 18, 2026 for OP Unit details.

20-03-2026

20-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 20, 2026, announcing a press release stating that its RAD division has booked an order for 5 RIO 360 units destined for the Downtown Civic Center in a major Midwest city. This development underscores demand for AITX's AI-driven security solutions amid otherwise limited financial details in the filing.

• ·Filing includes Exhibit 99.1: Press release dated March 20, 2026

20-03-2026

QIAGEN N.V. reported FY2025 net sales of $2.09B, up 6% YoY from $1.98B in FY2024, driven by 7% growth in consumables (90% of sales) and 10% increase in EMEA revenues. However, instrumentation sales declined 2% to $213.6M and Asia Pacific, Japan & Rest of World revenues fell 2% to $290.7M. Gross profit rose 34% to $1.30B with margin expansion to 62.2% from 48.9%, while product groups like Sample Technologies (+3%) and Other (+41%) showed varied performance.

• ·FY2023 total net sales were $1,965.3M.
• ·Instrumentation sales declined from $239.1M in FY2023 to $218.0M in FY2024 (-9%) and $213.6M in FY2025 (-2%).
• ·Employee functions stable: Sales 38% (up from 37%), Production 27% (down from 28%), R&D 17% (down from 18%) in FY2025.

20-03-2026

StimCell Energetics Inc. (OTCQB: STME) engaged Stonegate Capital Partners, Inc. for research coverage and institutional investor outreach under an Advisory Services Agreement effective March 12, 2026, with services including quarterly research updates and coordination of investor meetings for a 12-month term. Compensation consists of 250,000 shares of common stock issued to Stonegate. CEO David Jeffs highlighted the partnership's potential to elevate visibility and build institutional ownership for the company's eBalance® technology.

• ·Shares subject to a six-month hold period from issuance date.
• ·Shares issued pursuant to exemptions from prospectus requirements of Canadian securities laws and registration requirements of U.S. Securities Act of 1933.
• ·Company focuses on products enhancing cellular function for wellness, anti-aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function.

20-03-2026

Civista Bancshares, Inc. issued a press release on March 19, 2026, announcing plans to release its first quarter 2026 financial results prior to market open on April 22, 2026. The company is a $4.4B financial holding company headquartered in Sandusky, Ohio, with primary subsidiary Civista Bank operating 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884
• ·Civista Leasing and Finance Division headquartered in Pittsburgh, Pennsylvania
• ·Common shares traded on NASDAQ under symbol CIVB
• ·Website: www.civb.com

20-03-2026

Dollar General's FY2025 net sales rose 5.2% YoY to $42.7B from $40.6B in FY2024, driven by 6.7% growth in home products and 6.2% in seasonal, while consumables grew 5.0% and apparel a modest 3.3%; average sales per square foot increased to $270 from $263. Operating profit surged 28.6% to $2.2B with gross margin expanding 107 bps to 30.66%, and net income climbed 34.4% to $1.5B. However, profitability metrics remained below FY2023 levels, with operating profit down 29.9% from $2.4B and net margin at 3.54% versus 4.29%.

• ·Average sales per square foot: $270 in FY2025 (up from $263 in FY2024)
• ·FY2025 SG&A expenses: $10.9B (5.8% YoY increase)
• ·FY2025 diluted EPS: $6.85 (34.1% YoY increase from $5.11)
• ·Self-insurance liabilities: $377.6M total

20-03-2026

The Board is actively overseeing AI integration, including appointing a Chief Artificial Intelligence Officer, establishing governance frameworks, and participating in executive education programs. As of December 31, 2025, employee headcount grew 10.2% YoY by 33 to 328 (326 full-time, 2 part-time), driven by business expansion and risk management strengthening, while gender diversity remained flat at 45% women and 55% men. The Board held 14 meetings in 2025 with an average attendance of 95%, and all directors attended the 2025 annual stockholder meeting.

• ·No employees represented by collective bargaining agreement.
• ·Board has four standing committees: Audit, Risk, CG&N, and Compensation (implied).
• ·Audit Committee oversees independent auditors, financial statements, and internal audit function.

20-03-2026

On March 13, 2026, Bowman Consulting Group Ltd. (BWMN) entered into a $146.7M contract amendment with a US government agency, increasing the total contract value to $177.7M from the original contract signed in December 2025. Bowman's services under this contract are expected to span 36 months. This represents a significant new revenue opportunity for the emerging growth company.

• ·Original contract entered into in December 2025.
• ·Registrant is an emerging growth company.
• ·Principal executive offices: 12355 Sunrise Valley Drive, Suite 520, Reston, Virginia 20191.

20-03-2026

Milestone Pharmaceuticals reported first-year revenue of $1.5M for the year ended December 31, 2025, up 100% from $0 in 2024 following the US launch of CARDAMYST nasal spray, supported by a sales team of approximately 60 representatives targeting cardiology and primary care providers for an estimated 500,000 PSVT patients in 2026. However, total operating expenses rose 51.3% to $63.7M, driven by a 157.2% surge in commercial expenses to $28.3M and 26.1% increase in R&D to $18.1M, resulting in a widened net loss of $63.1M (51.9% worse than $41.5M in 2024). The company anticipates continued substantial operating losses until CARDAMYST revenue suffices.

• ·Company has incurred significant operating losses since inception and anticipates continued losses until CARDAMYST revenue is sufficient.
• ·Pursuing clinical development for subsequent etripamil indications beyond PSVT.

20-03-2026

Naveen Krishna, Executive Vice President and Chief Information & Digital Officer of Genuine Parts Company (GPC), notified his voluntary resignation effective April 1, 2026, to pursue other opportunities, with no severance benefits provided. He will remain an employee until May 5, 2026, to ensure an orderly transition. The company plans to reallocate his responsibilities to other individuals without appointing a successor at this time.

• ·Event reported on March 18, 2026; filing dated March 20, 2026
• ·GPC common stock trades as GPC on NYSE

20-03-2026

PEDEVCO Corp. published an updated company presentation on its website (www.pedevco.com) on March 20, 2026, furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. The filing includes standard forward-looking statements disclaimers and references to prior SEC filings like the Form 10-K for year ended December 31, 2024, and Form 10-Q for quarter ended September 30, 2025. No specific financial metrics, performance data, or period-over-period comparisons are disclosed in the filing.

• ·Company address: 575 N. Dairy Ashford, Suite 210, Houston, Texas 77079
• ·Common Stock trades on NYSE American under symbol PED

20-03-2026

Arrowhead Pharmaceuticals held its 2026 Annual Meeting of Stockholders on March 19, 2026, where all seven director nominees were elected despite significant opposition for some, such as Michael Perr (70.4M FOR vs. 31.3M AGAINST), Hongbo L (92.7M FOR vs. 9.0M AGAINST), and William Waddill (91.9M FOR vs. 9.9M AGAINST). The advisory Say-on-Pay proposal failed decisively with 41.6M FOR and 60.0M AGAINST, while the Amended and Restated 2021 Incentive Plan passed with 99.2M FOR and ratification of KPMG LLP as auditors passed overwhelmingly with 119.1M FOR.

• ·Record date for Annual Meeting: January 22, 2026
• ·Fiscal year for KPMG audit: ending September 30, 2026
• ·Christopher Anzalon director votes: 100,146,366 FOR; 1,622,011 AGAINST; 77,607 ABSTAIN
• ·Mauro Ferrar director votes: 99,784,848 FOR; 1,986,678 AGAINST; 74,458 ABSTAIN
• ·Hongbo L director votes: 92,692,428 FOR; 8,971,012 AGAINST; 182,544 ABSTAIN
• ·Adeoye Olukoto director votes: 100,808,855 FOR; 852,631 AGAINST; 184,498 ABSTAIN
• ·Victoria Vakiene director votes: 99,264,191 FOR; 2,506,051 AGAINST; 75,742 ABSTAIN
• ·William Waddill director votes: 91,907,466 FOR; 9,861,644 AGAINST; 256,341 ABSTAIN
• ·Say-on-Pay: 256,341 ABSTAIN
• ·Incentive Plan: 2,401,793 AGAINST; 285,915 ABSTAIN
• ·KPMG ratification: 371,668 AGAINST; 376,706 ABSTAIN

20-03-2026

The Hackett Group, Inc. (HCKT) filed its DEF 14A proxy statement for the 2026 Annual Meeting on April 30, 2026, seeking shareholder approval for electing one director nominee, amending the Employee Stock Purchase Plan to add 250,000 authorized shares and extend its term to July 1, 2031, an advisory vote on executive compensation, and ratification of RSM US LLP as auditors for the fiscal year ending January 1, 2027. The record date is March 13, 2026, with proxy materials distributed on or about March 20, 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting location: 1001 Brickell Bay Drive, 30th Floor, Miami, Florida at 11:00 a.m. local time
• ·Fiscal year for auditor ratification ends January 1, 2027
• ·Shareholder list available for examination 10 days prior to meeting

20-03-2026

Benitec Biopharma Inc. reported FY2025 total assets of $99.6M, nearly doubling from $52.2M YoY, with cash and equivalents surging 92% to $97.7M supported by $70.5M in net financing proceeds. However, net loss expanded 74% to $37.9M from $21.8M, driven by operating expenses rising 86% to $41.8M, including G&A expenses ballooning 335% to $23.4M and R&D up 17% to $18.3M. The amended 10-K includes restatements of prior interim periods reclassifying $7.3M from additional paid-in capital to accumulated deficit with no impact on total equity.

• ·EPS improved to $(1.05) from $(1.22) YoY despite wider loss, due to increased share count.
• ·Share-based compensation expense rose sharply to $17.4M in FY2025 from $0.8M.
• ·Restatement adjustment as of March 31, 2025: $7.3M reclassified from APIC to accumulated deficit, no equity impact.
• ·Cash, cash equivalents, and restricted cash end of FY2025: $97.9M vs $50.9M beginning.

20-03-2026

PhenixFIN Corporation held its Annual Meeting of Stockholders on March 20, 2026, electing directors Karen Hirtler-Garvey (1,037,446 For, 39,153 Withheld) and Lowell W. Robinson (968,775 For, 107,824 Withheld) for three-year terms, ratifying KPMG LLP as independent auditor for the fiscal year ending September 30, 2026 (1,412,772 For), and approving an advisory vote on executive compensation (956,003 For). All proposals passed with requisite majorities amid 348,153 broker non-votes for Proposals 1 and 3, with a quorum of 1,424,752 shares present out of 2,000,560 outstanding as of the January 23, 2026 record date. While approvals were strong, notable opposition included higher withheld votes for Robinson and 90,616 abstentions on compensation.

• ·Record date for stockholders entitled to vote: January 23, 2026
• ·Fiscal year end for auditor ratification: September 30, 2026
• ·Former names: Medley Capital Corp (name change 2011-01-18), Medley Capital BDC LLC (name change 2010-04-26)

20-03-2026

Stock Yards Bancorp (SYBT) is advancing its merger with Field & Main Bancorp via this S-4/A filing, with an exchange ratio of 0.6550 shares of SYBT common stock per Field & Main share, implying a value drop from $44.55 on January 26, 2026, to $41.25 on March 19, 2026, due to SYBT's stock price declining from $68.01 to $62.98 (-7.4%). Both companies maintain quarterly dividends at $0.32 and $0.25 per share, respectively, with coordination to avoid overlaps post-merger. SYBT has 29.5M shares outstanding and ~1,980 holders, while Field & Main has 2.37M shares and ~225 holders.

• ·SYBT stock price fluctuated between $62.09 low and $71.20 high from Jan 26 to Mar 19, 2026.
• ·Field & Main Bancorp common stock has no established public trading market.

20-03-2026

Intelligent Protection Management Corp. (IPM) furnished an investor presentation reporting Full Year 2025 revenue of $23.6M and Q4 2025 revenue of $6.1M, with net loss declining 42% YoY and Adjusted EBITDA turning positive in Q4, marking the first operational quarter post-transformation in Q1 2025. The company acquired Newtek Technology Solutions from NewtekOne in January 2025 for $4.0M cash and 4.0M shares of non-voting convertible preferred stock, adding over 50 employees and more than 17,000 customers, while divesting non-core legacy businesses for $1.4M plus up to $5M in earn-outs. No declines in revenue were reported, though historical net losses persist despite improvement.

• ·Q4 2025 Revenue Breakdown: Managed Information Technology $3.9M, Procurement $0.4M, Professional Services $1.5M, Subscription $0.3M
• ·Full Year 2025 Revenue Breakdown: Managed Information Technology $14.8M, Procurement $5.4M, Professional Services $1.1M, Subscription $2.3M
• ·Data center leases through 2032
• ·Historical gross margins of 50-55%

20-03-2026

Hope Bancorp, Inc. disclosed that directors David P. Malone and Lisa K. Pai notified the company of their intent to retire from the Board effective at the 2026 Annual Meeting of Stockholders, and they will not stand for re-election. Mr. Malone will continue as chair of the Board Risk Committee, and Ms. Pai as a member of the Board Risk Committee and Executive Committee until their terms end. The retirements are not due to any disagreements with the company's operations, policies, or practices.

• ·Filings signed by Kevin S. Kim on March 20, 2026.
• ·Company address: 3200 Wilshire Boulevard, Suite 1400, Los Angeles, California 90010.
• ·Common stock trades as HOPE on NASDAQ Global Select Market, par value $0.001 per share.

20-03-2026

On March 19, 2026, H. Gail Sandford, a director at Rigetti Computing, Inc., notified the company that she will not stand for re-election to the Board of Directors at the expiration of her current term during the 2026 Annual Meeting of Stockholders. Her decision was not due to any disagreement with the company's operations, policies, or practices. The company thanked her for her service.

20-03-2026

Firdaus Bhathena, Chief Product Technology Officer of Fidelity National Information Services, Inc. (FIS), notified the company of his resignation effective March 20, 2026, on March 18, 2026. No reason for departure or successor announcement was provided in the 8-K filing dated March 20, 2026. This executive change occurs without any disclosed impact on operations or financials.

20-03-2026

60 Degrees Pharmaceuticals, Inc. disclosed via 8-K an error in its March 13, 2026 Prospectus Supplement, where an affiliate's beneficially owned common shares were incorrectly reported as 21,490 shares instead of the correct 23,367 shares. The error stemmed from inaccurate totals in prior Form 4 filings on September 15, 2025, and December 16, 2025, with the corrected post 1-for-4 reverse stock split total at 16,781 shares versus the previously reported 15,905 shares. No other information in the Prospectus Supplement is affected.

• ·Error originated from Form 4 filed September 15, 2025, carried forward to Form 4 on December 16, 2025
• ·Company is an emerging growth company
• ·Securities: Common Stock (SXTP) and Warrants (SXTPW) on Nasdaq

20-03-2026

Climb Global Solutions, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation, authorizing a total of 40,010,000 shares: 40,000,000 common shares (par value $0.01) and 10,000 preferred shares (par value $0.01). Effective at 4:01 p.m. Eastern Time on March 20, 2026, each outstanding common share will be subdivided into four shares in a 4-for-1 stock split. The amendment was approved solely by the Board of Directors pursuant to DGCL Section 242(d)(1), without stockholder approval.

• ·Previous amendments to Certificate of Incorporation: July 21, 1995 (restated), August 21, 2006, and October 25, 2022.
• ·Par value for both common and preferred stock: $0.01 per share.

20-03-2026

Bain Capital GSS Investment Corp. (BCSS-WT) filed its 10-K annual report on March 20, 2026, presenting financial statements for the period from inception on March 24, 2025, through December 31, 2025, including balance sheet, statement of operations, changes in shareholders' deficit, and cash flows. The filing defines key terms such as private placement units, shares, and warrants issued to the sponsor simultaneously with the initial public offering and notes potential post-business combination risks like change in control or debt burdens. No operational performance metrics or period-over-period comparisons are detailed in the provided content.

• ·Financial statements as of December 31, 2025, and for the period March 24, 2025 (inception) through December 31, 2025
• ·Includes Report of Independent Registered Public Accounting Firm and Notes to Financial Statements (F-7 to F-18)

20-03-2026

Horizon Bancorp, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders, to be held virtually on May 7, 2026, at 10:00 a.m. CDT, with a record date of March 13, 2026. Shareholders will vote on electing four directors for three-year terms expiring in 2029, an advisory (non-binding) vote to approve executive compensation, and ratification of Forvis Mazars, LLP as the independent registered public accounting firm for 2026. The proxy materials and Annual Report for the year ended December 31, 2025, are available online, with printed copies available upon request.

• ·Virtual meeting access: www.meetnow.global/MGRACXW using 15-digit control number.
• ·Street name holders must register legal proxy by April 17, 2026, 9:00 a.m. CDT.
• ·Proxy materials mailed as Notice on March 18, 2026; available at www.investorvote.com/hbnc.

20-03-2026

On March 18, 2026, Black Rock Coffee Bar, Inc. entered into an irrevocable proxy with the Jacob V. Spellmeyer 2021 Trust, Juliet A. Spellmeyer 2021 Trust, Bryan D. Pereboom 2021 Trust, and Nicole R. Pereboom 2021 Trust, all Class C common shareholders, granting the Company, its CEO, or designees authority to vote their Covered Shares (Class A, B, or C common stock) until the later of two years from March 18, 2026, or termination of the September 11, 2025 Voting Agreement. The Proxy Parties are also parties to the Voting Agreement involving Viking Cake Fuel, LLC and Viking Cake Fuel II, LLC. No financial terms or performance metrics were disclosed.

• ·Proxy filed as Exhibit 10.1
• ·Voting Agreement dated September 11, 2025
• ·Proxy effective until later of March 18, 2028 or Voting Agreement termination

20-03-2026

Palisade Bio, Inc. reported a widened net loss of $16.8M for the year ended December 31, 2025, up 16% YoY from $14.4M, driven by a 22% increase in total operating expenses to $18.1M (R&D up 12% to $10.2M, G&A up 36% to $7.9M). However, cash and equivalents surged to $133.4M from $9.8M, fueled by $134.4M in net financing activities primarily from equity offerings and warrant exercises, while cash used in operations improved slightly to $10.8M from $12.2M.

• ·Basic and diluted net loss per common share improved to $(0.30) from $(10.19) YoY due to increased share count.
• ·Total assets increased to $134.3M from $10.9M; stockholders' equity to $129.4M from $7.5M.
• ·Stock-based compensation expense rose to $4.0M from $0.7M.
• ·Proceeds from issuance of common stock and warrants net: $128.2M in 2025 vs $8.4M in 2024.

20-03-2026

Genco Shipping & Trading Ltd (GNK) filed a DEFA14A on March 20, 2026, announcing its intent to file a definitive proxy statement on Schedule 14A and accompanying WHITE proxy card with the SEC for the 2026 Annual Meeting of Shareholders. The filing discloses participants in the proxy solicitation, including independent directors (Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan) and executives (John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen), with references to prior SEC filings for ownership details. Shareholders are strongly encouraged to review these materials available on SEC.gov and the company's investor relations website at https://investors.gencoshipping.com/.

• ·Prior proxy statement for 2025 Annual Meeting filed with SEC on April 9, 2025.
• ·Form 4 filings for directors and executives on dates including May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026.
• ·Investor contact: Peter Allen at (646) 443-8550; Media contact: Leon Berman at (212) 477-8438.

20-03-2026

Chain Bridge Bancorp reported net income of $20.2M for the year ended December 31, 2025, down 3.4% YoY from $20.9M in 2024, driven by a sharp 59.4% decline in noninterest income to $3.5M despite robust 16.1% growth in net interest income to $51.5M. Average total assets expanded 19.0% to $1.54B, but noninterest expenses increased 12.0% to $30.1M and net interest margin compressed slightly to 3.39% from 3.46%. While taxable securities interest surged 77.3% to $21.8M, loan interest fell 3.6% to $13.3M and deposit placement services revenue plummeted 86.5% to $0.8M.

• ·Recapture of credit losses increased to $0.5M from $0.2M (205.6% YoY).
• ·Average interest-earning assets grew to $1.52B from $1.28B.
• ·Tier 1 capital, leverage, and total capital ratios not provided in excerpt.
• ·Charter effective October 3, 2024.

20-03-2026

Wilson Bank Holding Company (WBHC) highlights strong 2025 performance in its DEF 14A proxy statement, with total assets exceeding $5B and loan growth of $259.2M driven by relationship banking and stable core deposits. The filing accompanies notice for the April 23, 2026 annual shareholder meeting to elect four Class I directors for three-year terms and ratify RubinBrown LLP as independent auditors for FY 2026. No declines or flat metrics are disclosed.

• ·Annual meeting on Thursday, April 23, 2026 at 5:00 p.m. CDT at Clemons-Richerson Operations Center, 105 North Castle Heights Avenue, Lebanon, TN 37087
• ·Elect four Class I directors to hold office for three years until successors elected and qualified
• ·Ratify appointment of RubinBrown LLP as independent registered public accounting firm for fiscal year ending December 31, 2026
• ·2025 Annual Report enclosed highlighting financial performance

20-03-2026

On March 20, 2026, EyePoint, Inc. filed a complaint against Ocular Therapeutix, Inc. in Middlesex County Superior Court, alleging defamation, commercial disparagement, violation of Mass. Gen. L. c. 93A, and tortious interference related to false or misleading statements about the Company's lead product candidate DURAVYU™ (vorolanib intravitreal insert). The Company seeks injunctive relief to prevent further dissemination, public retraction of the statements, monetary damages, attorneys’ fees, and costs. This disclosure under Item 7.01 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.

20-03-2026

Affinity Bancshares, Inc. (AFBI) reported improved asset quality in its 10-K, with total non-accrual loans declining 25% YoY to $3.57M and the non-performing loans ratio improving to 0.48% from 0.67%, while loans grew to $742.7M. Net interest income increased 6.8% to $31.1M with net interest margin expanding slightly to 3.59%, and non-interest expenses decreased 8.7% to $21.7M. However, stockholders' equity fell marginally to $127.0M from $129.1M, non-interest-bearing deposits dropped 12% to $132.8M, and retained earnings were flat at $76.1M.

• ·Net interest rate spread widened to 2.75% from 2.59%.
• ·Interest sensitivity analysis shows net interest income forecast at $32.6M at level rates, declining up to 8.27% if rates rise +400 bps.
• ·Allowance for credit losses on loans increased to $9.0M from $8.5M.
• ·Investment securities total amortized cost $43.6M at Dec 31 2025 with weighted average yield 3.53%.
• ·Common shares outstanding decreased to 6,095,631 from 6,409,598.

20-03-2026

Additional proxy materials dated March 20, 2026, provide information for the Joint Annual Meeting of Stockholders of AGHIF and ANMIF on March 30, 2026. During the fiscal year ended 2025, AGHIF's Board and Audit Committee each met 4 times, while ANMIF's Board met 6 times and Audit Committee 4 times, with all Directors attending at least 75% of meetings except Mr. Chaloff, who attended less than 75% of ANMIF Board meetings.

• ·Fiscal year end: March 31
• ·SEC file number: 811-07732

20-03-2026

20-03-2026

Community West Bancshares filed a Form 8-K on March 20, 2026 (AccNo: 0001628280-26-020231), reporting under Item 8.01 Other Events. No details on the specific event, transaction value, financial impacts, or any metrics are disclosed in the provided filing information. This appears to be a single-item, voluntary disclosure.

20-03-2026

UNITED SECURITY BANCSHARES filed an 8-K on March 20, 2026, reporting under Item 8.01 Other Events. No specific details regarding the core event, financial impacts, quantitative metrics, or other material information are disclosed in the provided filing metadata. Analysis is constrained by the absence of filing content beyond the item identification.

20-03-2026

Global Indemnity Group, LLC (GBLI) appointed Evan J. Kasowitz, age 36, as Chief Operating Officer effective March 20, 2026. Mr. Kasowitz, who has served as President of Belmont Holdings since March 2025 and in other senior roles since 2021, entered a compensatory arrangement with a $700,000 base salary and cash/equity bonus tiers each up to 100% of base salary. There are no related arrangements, understandings, or family relationships.

• ·Mr. Kasowitz previously served as Senior Vice President – Operations since May 2023 and other senior officer positions since August 2021.
• ·Mr. Kasowitz earned BA degrees in Biology and Economics from Bucknell University, MBA from St. Joseph’s University, and holds CPCU and Associate in Reinsurance designations.

20-03-2026

XORTX Therapeutics Inc. reported cash and cash equivalents declining 65% YoY to $864,514 as of December 31, 2025 from $2,473,649 in 2024, signaling significant cash burn, while accounts payable and accrued liabilities surged 276% to $553,784. Derivative warrant liability improved sharply, dropping 99% to $8,000 from $572,000. The company issued 1,528,272 warrants in 2025 at prices ranging from $0.69 to $1.20.

• ·Warrants issued at $1.20 on July 21 (1,283,923) and August 8 (156,849), 2025; at $0.69 on October 23 (87,500), 2025.
• ·Contractual obligations as of Dec 31, 2025: $576,014 due <3 months, $15,057 due 3-12 months.
• ·Disclosures highlight risks from U.S. federal False Claims Act, anti-kickback laws, state laws, and Physician Payments Sunshine Act.

20-03-2026

EWSB Bancorp, Inc. filed amended and restated bylaws governing stockholder meetings, including procedures for annual and special meetings called by the President, CEO, Chairperson, Board, or stockholders holding a majority of votes. The bylaws specify notice requirements (10-90 days), quorum (majority of shares), adjournment/postponement rules (up to 120 days), and strict advance notice for business proposals and director nominations (90-100 days prior to annual meeting anniversary, with adjustments for changes in meeting dates). Special provisions apply to the first annual meeting after becoming sole stockholder of East Wisconsin Savings Bank.

• ·Special meetings called only by President, CEO, Chairperson, Board (majority of Whole Board), or stockholders entitled to majority of votes, with Board fixing record date, meeting details.
• ·Stockholder notice for proposals/nominations: delivered 90-100 days before prior year's annual meeting anniversary; if advanced >30 days, between public disclosure and 10th day after.
• ·Notice by electronic transmission per Maryland General Corporation Law; waivers allowed.

20-03-2026

Highpoint Community Bank, a subsidiary of HCB Financial Corp., has agreed to merge with Independent Bank Corporation (IBCP), a Grand Rapids, Michigan-based community bank, in a transaction expected to close later in 2026 subject to shareholder and regulatory approvals. The merger is positioned to enhance customer benefits including access to a broader branch and ATM network, improved digital banking tools, extended support hours, and expanded lending solutions while maintaining the existing community banking model and team. No financial terms or quantitative impacts are disclosed in this customer letter.

• ·Independent Bank formally approached HCB late last year (2025).
• ·Independent intends to file a registration statement on Form S-4 with the SEC, including a prospectus and proxy statement.
• ·Documents available free at www.sec.gov or by request to Independent Bank Corporation, Attn: CFO, 4200 East Beltline Avenue NE, Grand Rapids, MI 49525, phone 800.355.0641.

20-03-2026

West Enclave Merger Corp., a Cayman Islands blank check company incorporated on December 9, 2025, filed an S-1/A registration statement on March 20, 2026, for an IPO of 10,000,000 units at $10.00 each, targeting gross proceeds of $100M ($98M net before expenses), with $100.25M to be deposited in trust (or $115.29M if over-allotment exercised). The SPAC plans to pursue a business combination within 21 months of closing, focusing on high-quality businesses in Latin America or U.S. operations benefiting from the region, accompanied by private units and a $250K EBC loan. No operational revenues have been generated to date, and investing involves high risks as noted in the Risk Factors section.

• ·Over-allotment option for 1,500,000 additional units.
• ·Business combination must complete within 21 months from offering closing or public shares redeemable.
• ·Company is an emerging growth company with reduced reporting requirements.
• ·No revenues generated to date; efforts limited to organizational activities and offering.

20-03-2026

REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC (GSK) on March 18, 2026, resolving a dispute over sublicense fees under their 2009 License Agreement. The Company agreed to pay GSK $10 million within three business days for alleged underpayments on royalties and other sublicensee amounts, representing a cash outflow. The agreement provides mutual releases of past claims and certain future claims while allowing the Company to continue its existing payment allocation methodology.

• ·Settlement Agreement effective date: March 18, 2026
• ·Payment due within three business days of effective date
• ·Full Settlement Agreement to be filed with Quarterly Report on Form 10-Q for quarter ending March 31, 2026

20-03-2026

IP Strategy Holdings, Inc. (IPST) received a Nasdaq notice on March 20, 2026, stating that its common stock failed the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2), with the closing bid price below $1.00 for 30 consecutive business days. The company is ineligible for the standard 180-calendar-day compliance period due to a prior 1-for-20 reverse stock split on November 5, 2025, prompting plans to appeal by March 27, 2026, and a special stockholder meeting on April 10, 2026, to approve another reverse stock split (1:3 to 1:20). No assurance exists that these actions will enable regaining compliance before the Nasdaq hearing.

• ·Record date for special stockholder meeting: March 19, 2026
• ·Appeal filing deadline: no later than March 27, 2026
• ·Nasdaq Listing Rule cited: 5550(a)(2) and 5810(c)(3)(A)(iv)